Abivax annual r&d spending
2021
2022
2023
2024
2025
Abivax R&D Spending Growth & History (ABVX)
Abivax's r&d spending was €177.8M for fiscal 2025.
View full Abivax company overviewAbivax annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €177.8M | €31.2M | +21.31% |
| 2024 | 2024-12-31 | €146.5M | €43.4M | +42.02% |
| 2023 | 2023-12-31 | €103.2M | €54.9M | +113.64% |
| 2022 | 2022-12-31 | €48.3M | €514,000 | +1.08% |
| 2021 | 2021-12-31 | €47.8M | — | — |
Abivax quarterly r&d spending
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | €49.5M | €10.2M | +26.06% |
| Q4 2025 | 2025-12-31 | €44.4M | €5.8M | +15.04% |
| Q3 2025 | 2025-09-30 | €55.4M | €12.1M | +28.02% |
| Q2 2025 | 2025-06-30 | €38.6M | €9.7M | +33.69% |
| Q1 2025 | 2025-03-31 | €39.3M | €3.6M | +9.95% |
| Q4 2024 | 2024-12-31 | €38.6M | — | — |
| Q3 2024 | 2024-09-30 | €43.3M | — | — |
| Q2 2024 | 2024-06-30 | €28.9M | — | — |
| Q1 2024 | 2024-03-31 | €35.7M | — | — |
Abivax r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Abivax's r&d spending increased from €47.8M to €177.8M, a change of €130.0M. The latest reported quarter, Q1 2026, shows €49.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abivax source filings ↗